Impact of Race and Ethnicity on Inflammatory Bowel Disease

Basu, Dhiman; Lopez, Ivelisse; Kulkarni, Aparna; Sellin, Joseph H.

doi:10.1111/j.1572-0241.2005.00233.x

Cited by 148 publications

(137 citation statements)

References 24 publications

Supporting

Mentioning

120

Contrasting

Unclassified

Order By: Relevance

“…Previous studies indicated substantial racial/ethnic differences in the characteristics of IBD in the United States and worldwide [1,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24]. Little data exists with regard to the prevalence of IBD in Blacks in the United States and in Asians outside Asia [23].…”

Section: Introductionmentioning

confidence: 99%

Racial/Ethnic and Regional Differences in the Prevalence of Inflammatory Bowel Disease in the United States

Wang

Loftus²,

Cangemi

et al. 2013

Digestion

View full text Add to dashboard Cite

Background: The magnitude of racial/ethnic and regional differences in the prevalence of inflammatory bowel disease (IBD) in the United States remains largely unknown. Aims: To estimate differences in the prevalence of IBD by race/ethnicity and region. Methods: The Medical Expenditure Panel Survey, a nationally representative survey of US households and medical conditions, was used. A multivariate logistic model was used in statistical analysis. Results: Among 202,468 individuals surveyed during 1996-2007, 316 were diagnosed with IBD (26 Blacks, 21 Hispanics, and 5 Asians). The prevalence of IBD was higher in Whites [Crohn's disease: 154; ulcerative colitis (UC): 89] than Blacks (Crohn's disease: 68; UC: 25), Hispanics (Crohn's disease: 15; UC: 35), and Asians (Crohn's: 45; UC: 40) (all p < 0.05, except for UC in Asians). The differences in Crohn's disease between Whites and minorities and the difference in UC between Whites and Blacks remained significant in multivariate analysis. In multivariate analysis, there was no regional difference in the prevalence of Crohn's disease, but the prevalence of UC was higher in the Northeast than the South (p < 0.05). Conclusions: There were significant racial/ethnic differences in the prevalence of IBD in the USA. The underlying etiology of these differences warrants additional research.

show abstract

Section: Introductionmentioning

confidence: 99%

Racial/Ethnic and Regional Differences in the Prevalence of Inflammatory Bowel Disease in the United States

Wang

Loftus²,

Cangemi

et al. 2013

Digestion

View full text Add to dashboard Cite

show abstract

“…Yet, recently reported data have supported the supposition that IBD is no longer a rarity in non-Caucasians, although still less common than in the Caucasian population [1,2]. Also, inflammatory bowel disease may be increasing in incidence in certain US minority populations, including AfricanAmericans, according to hospital statistics [3][4][5].…”

mentioning

confidence: 83%

Patient-Reported Outcomes in Crohn’s Disease: Does Race Matter?

Horst

2014

Dig Dis Sci

View full text Add to dashboard Cite

“…Several distinct genetic and environmental factors contribute to the pathogenesis of IBD, which is probably modulated by their complex interaction (8,9). Initial evidence for a genetic predisposition to the development of IBD stems from the observation of differences in the incidence of IBD between different ethnic groups (10). There is welldocumented evidence that Caucasians in Europe and North America have the highest rates of IBD, followed by Afro-Americans and then Asians (11).…”

Section: Chronic Inflammatory Bowel Diseases (Ibd) Includingmentioning

confidence: 99%

No association between the functional cannabinoid receptor type 2 Q63R variants and inflammatory bowel disease in Turkish subjects

Yönal

Eren²,

Yılmaz³

et al. 2015

Turk J Gastroenterol

View full text Add to dashboard Cite

Background/Aims: The endocannabinoid system can exert beneficial effects on gastrointestinal inflammation, and cannabinoid receptor-2 (CB2) agonists may represent a new therapeutic approach in inflammatory bowel disease (IBD). A functional CB2 Q63R polymorphism (rs35761398) in the CNR2 gene has been shown to affect the immunomodulating properties of the CB2 receptor. We sought to investigate whether the functional CB2 Q63R polymorphism (rs35761398) is associated with IBD susceptibility in a Turkish clinical sample. Materials and Methods: A total of 202 IBD patients, comprising 101 Crohn's disease (CD) patients and 101 ulcerative colitis (UC) patients, and 101 healthy controls were included in the study. The CB2 Q63R polymorphism was genotyped using real-time PCR. Results: There were no significant differences in the genotype frequencies of the three study groups. The odds ratio of the minor Q allele for CD relative to the common R allele was not significant (OR =1.02, 95% CI =0.67-1.56, p=0.99). Similarly, the odds ratio of the minor Q allele for UC relative to the common R allele did not reach statistical significance (OR =1.10, 95% CI =0.72-1.68, p=0.75). Moreover, the genotype frequencies did not show any significant association with the disease extent in either CD (p= 0.71) or UC patients (p=0.59). Conclusion: These pilot findings suggest that CB2 Q63R polymorphism does not play a major role in genetic susceptibility to IBD or in its disease phenotypes among Turkish subjects.

show abstract

Impact of Race and Ethnicity on Inflammatory Bowel Disease

Abstract: There are significant differences in IBD subtypes and serologic markers among racial/ ethnic groups with IBD in the United States.

Cited by 148 publications

References 24 publications

Racial/Ethnic and Regional Differences in the Prevalence of Inflammatory Bowel Disease in the United States

Racial/Ethnic and Regional Differences in the Prevalence of Inflammatory Bowel Disease in the United States

Patient-Reported Outcomes in Crohn’s Disease: Does Race Matter?

No association between the functional cannabinoid receptor type 2 Q63R variants and inflammatory bowel disease in Turkish subjects

Contact Info

Product

Resources

About